ERBB2 and breast carcinoma: Among our study cohort of 129 ER/PR positive/HER2 negative breast cancer patients (Table 1), where PI3K signaling alteration is expected to be prevalent5, we observed a median follow-up of 53 months (95% confidence interval (CI) of 50–71 months).